Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
344.39
+2.45 (0.72%)
Feb 27, 2026, 4:00 PM EST - Market closed
Penumbra Revenue
In the year 2025, Penumbra had annual revenue of $1.40B with 17.50% growth. Penumbra had revenue of $385.39M in the quarter ending December 31, 2025, with 22.14% growth.
Revenue (ttm)
$1.40B
Revenue Growth
+17.50%
P/S Ratio
9.63
Revenue / Employee
$298,652
Employees
4,700
Market Cap
13.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 209.05M | 17.50% |
| Dec 31, 2024 | 1.19B | 136.09M | 12.86% |
| Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
| Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
| Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.23B |
| Smith & Nephew | 5.94B |
| STERIS | 5.83B |
| DexCom | 4.66B |
| Bruker | 3.44B |
| Globus Medical | 2.94B |
| Insulet | 2.71B |
| Bio-Rad Laboratories | 2.58B |
PEN News
- 3 days ago - Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 16 days ago - Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
- 24 days ago - Boston Scientific announces results for fourth quarter and full year 2025 - PRNewsWire
- 4 weeks ago - Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 5 weeks ago - Artisan Small Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 6 weeks ago - Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach - Invezz
- 6 weeks ago - Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. - Barrons
- 6 weeks ago - Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments - Market Watch